Innovative Diagnostic Expansion MeMed's recent launch of the MeMed BV test and ongoing development of rapid bacterial vs viral infection diagnostics present opportunities for partners looking to enhance clinical decision-making tools and expand their diagnostic portfolio.

Strategic Industry Position As a leader in host response technology with FDA-cleared products and recent partnerships in the UK and Ireland, MeMed is well-positioned to support healthcare providers seeking scalable, immune-based diagnostic solutions across international markets.

Robust Financial Backing With substantial revenues between 250 and 500 million dollars and recent funding of 93 million dollars, MeMed demonstrates strong financial health, enabling investment in new product development, sales channels, and strategic collaborations.

Healthcare Ecosystem Integration Having been acquired by Walmart in 2021, MeMed is strategically aligned to leverage retail and telehealth platforms, creating potential sales opportunities within broad consumer and healthcare networks seeking innovative testing solutions.

Leadership & Market Growth Recent leadership appointments and ongoing clinical advancements position MeMed for accelerated growth and market penetration, offering sales teams opportunities to collaborate with a forward-looking company committed to expanding diagnostic access.